Avidity Biosciences (RNA) Stock Price, News & Analysis

Company Overview

Avidity Biosciences is a clinical-stage biotechnology company dedicated to developing antibody-oligonucleotide conjugate (AOC) therapies designed to address serious neuromuscular and cardiac diseases. The company’s proprietary AOC platform combines the targeting specificity of monoclonal antibodies with the gene-modulating power of oligonucleotides to deliver therapeutic agents directly into muscle cells. Headquartered in La Jolla, California, Avidity seeks to overcome traditional delivery challenges associated with RNA-based medicines by leveraging receptor-mediated uptake mechanisms.

The company’s lead product candidate, AOC 1001, is in clinical development for myotonic dystrophy type 1 (DM1) and represents the first application of the AOC platform in a human study. Preclinical programs include additional neuromuscular indications such as Duchenne muscular dystrophy (DMD) and X-linked myotubular myopathy (XLMTM). Avidity’s research efforts focus on optimizing conjugate design, antibody selection, and oligonucleotide chemistries to maximize tissue uptake and therapeutic potency.

Avidity Biosciences was founded in 2017 by a team of scientists and entrepreneurs with expertise in antibody engineering, oligonucleotide chemistry and muscle biology. The company went public on the Nasdaq Global Market under the ticker RNA in January 2021. Laurent Fischer, M.D., serves as Chief Executive Officer, drawing on his background in immunology and drug discovery to guide the company’s strategic and clinical initiatives. Avidity maintains research and development operations in the United States and engages in collaborations to expand the reach of its AOC technology.

Building on its foundational platform, Avidity continues to advance multiple pipeline candidates through preclinical and clinical stages, while exploring partnership opportunities with biopharmaceutical companies. The company’s long-term objective is to transform the treatment landscape for patients with genetic muscle disorders by delivering precision RNA therapies with improved safety, efficacy and convenience.

Key Stats

• Today's Range: $11.45 to $11.89
• 50-Day Range: $11.55 to $14.54
• 52-Week Range: $11.45 to $16.77
• Volume: 201,686 shs
• Average Volume: 532,603 shs
• Market Capitalization: $201.17 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $70.00
• Consensus Rating: Hold

Avidity Biosciences Stock Analysis - MarketRank™

Avidity Biosciences scored higher than 55% of companies evaluated by MarketBeat, and ranked 696th out of 857 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 4.0 / 5
• Analyst Rating: Hold

Consensus Rating

Avidity Biosciences has received a consensus rating of Hold. The company's average rating score is 2.37, and is based on 1 strong buy rating, 6 buy ratings, 11 hold ratings, and 1 sell rating.

Upside Potential

Avidity Biosciences has a consensus price target of $69.42, representing about 490.3% upside from its current price of $11.76.

Amount of Analyst Coverage

Avidity Biosciences has only been the subject of 4 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.0 / 5
• Proj. Earnings Growth: Decreasing

Earnings Growth

Earnings for Avidity Biosciences are expected to decrease in the coming year, from ($2.89) to ($3.34) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Avidity Biosciences is -2.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Avidity Biosciences is -2.37, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Avidity Biosciences has a P/B Ratio of 1.08. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 2.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

2.45% of the float of Avidity Biosciences has been sold short.

Short Interest Ratio / Days to Cover

Avidity Biosciences has a short interest ratio ("days to cover") of 15.83, which indicates bearish sentiment.

Change versus previous month

Short interest in Avidity Biosciences has recently decreased by 2.11%, indicating that investor sentiment is improving.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Avidity Biosciences does not currently pay a dividend.

Dividend Growth

Avidity Biosciences does not have a long track record of dividend growth.

News and Social Media

• Score: 4.3 / 5
• News Sentiment: N/A

News Sentiment

Avidity Biosciences has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.81 average news sentiment score of Medical companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Avidity Biosciences this week, compared to 4 articles on an average week.

Search Interest

3 people have searched for RNA on MarketBeat in the last 30 days.

MarketBeat Follows

4 people have added Avidity Biosciences to their MarketBeat watchlist in the last 30 days.

Company Ownership

• Score: 0.1 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Avidity Biosciences insiders have not sold or bought any company stock.

Percentage Held by Insiders

3.83% of the stock of Avidity Biosciences is held by insiders.

Percentage Held by Institutions

Avidity Biosciences has minimal institutional ownership at this time.

Company Calendar

• Last Earnings: 5/14/2026
• Today: 6/09/2026
• Fiscal Year End: 12/31/2026

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Medical
• Industry: MED - BIOMED/GENE
• Sub-Industry: Pharmaceutical Products
• Current Symbol: NASDAQ:RNA
• CIK: 1599901
• Web: www.aviditybiosciences.com
• Phone: 858-401-7900
• Fax: N/A
• Employees: 190
• Year Founded: 2013

Price Target and Rating

• Average Price Target for Avidity Biosciences: $70.00
• High Price Target: $96.00
• Low Price Target: $55.00
• Potential Upside/Downside: +495.2%
• Consensus Rating: Hold
• Rating Score (0-4): 2.33
• Research Coverage: 18 Analysts

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$322.30 million
• Net Margins: -3,650.39%
• Pretax Margin: -3,650.39%
• Return on Equity: -44.92%
• Return on Assets: -39.57%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 9.20
• Quick Ratio: 11.57

Sales & Book Value

• Annual Sales: $36.68 million
• Price / Sales: 5.48
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $10.88 per share
• Price / Book: 1.08

Miscellaneous

• Outstanding Shares: 17,106,000
• Free Float: 149,208,000
• Market Cap: $201.17 million
• Optionable: Optionable
• Beta: 0.93